Shinpoong Pharmaceutical Co Ltd (019175) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shinpoong Pharmaceutical Co Ltd (019175) has a cash flow conversion efficiency ratio of 0.022x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩6.36 Billion ≈ $4.31 Million USD) by net assets (₩292.26 Billion ≈ $198.06 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Shinpoong Pharmaceutical Co Ltd balance sheet independence to measure how much of total assets are equity-financed.
Shinpoong Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Shinpoong Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Shinpoong Pharmaceutical Co Ltd (019175) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Shinpoong Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shinpoong Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Brite Tech Bhd
KLSE:0011
|
0.060x |
|
Betonjaya Manunggal Tbk
JK:BTON
|
0.062x |
|
All In! Games S.A.
WAR:ALG
|
-0.030x |
|
BEYOND MED TEC. INC. NEW
F:7FM
|
N/A |
|
BTC Health Ltd
AU:BTC
|
-0.023x |
|
Frtek Co.Ltd
KQ:073540
|
0.029x |
|
Envoy Medical Inc.
NASDAQ:COCH
|
0.575x |
|
Bal Pharma Limited
NSE:BALPHARMA
|
0.123x |
Annual Cash Flow Conversion Efficiency for Shinpoong Pharmaceutical Co Ltd (2014–2025)
The table below shows the annual cash flow conversion efficiency of Shinpoong Pharmaceutical Co Ltd from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see Shinpoong Pharmaceutical Co Ltd market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩270.73 Billion ≈ $183.47 Million |
₩17.25 Billion ≈ $11.69 Million |
0.064x | +208.54% |
| 2024-12-31 | ₩258.09 Billion ≈ $174.90 Million |
₩-15.15 Billion ≈ $-10.27 Million |
-0.059x | +35.91% |
| 2023-12-31 | ₩270.78 Billion ≈ $183.51 Million |
₩-24.81 Billion ≈ $-16.81 Million |
-0.092x | -14.59% |
| 2022-12-31 | ₩330.76 Billion ≈ $224.15 Million |
₩-26.44 Billion ≈ $-17.92 Million |
-0.080x | +60.09% |
| 2021-12-31 | ₩354.56 Billion ≈ $240.28 Million |
₩-71.03 Billion ≈ $-48.13 Million |
-0.200x | -473.78% |
| 2020-12-31 | ₩374.33 Billion ≈ $253.68 Million |
₩20.06 Billion ≈ $13.60 Million |
0.054x | -42.08% |
| 2019-12-31 | ₩209.13 Billion ≈ $141.72 Million |
₩19.35 Billion ≈ $13.11 Million |
0.093x | -40.11% |
| 2018-12-31 | ₩207.48 Billion ≈ $140.61 Million |
₩32.05 Billion ≈ $21.72 Million |
0.154x | +219.87% |
| 2017-12-31 | ₩210.11 Billion ≈ $142.39 Million |
₩10.15 Billion ≈ $6.88 Million |
0.048x | -44.76% |
| 2016-12-31 | ₩216.85 Billion ≈ $146.96 Million |
₩18.96 Billion ≈ $12.85 Million |
0.087x | +72.25% |
| 2015-12-31 | ₩194.86 Billion ≈ $132.05 Million |
₩9.89 Billion ≈ $6.70 Million |
0.051x | +20285.41% |
| 2014-12-31 | ₩191.51 Billion ≈ $129.79 Million |
₩-48.16 Million ≈ $-32.64K |
0.000x | -- |
About Shinpoong Pharmaceutical Co Ltd
Shinpoong Pharmaceutical Co.,Ltd, together with its subsidiaries, manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products, as well as antivirals, anticancer drugs, painkillers, anti-inflammatory products, and anthelmintics. It provides active pharmaceutical ingredients; Pyramax, an anti-malarial dru… Read more